Core Scientific (CORZ) has been upgraded to "outperform" by Macquarie, with a revised price target of $34, following the collapse of its merger with CoreWeave (CRWV). The failed merger, which faced shareholder opposition, is viewed positively as it allows Core Scientific to lease its power capacity to AI tenants. The company currently manages a 1.5 GW portfolio, including 590 MW leased to CoreWeave and 700 MW billable. Jefferies highlighted that Core Scientific is refocusing its strategy, aiming to secure new colocation customers by the fourth quarter. With its substantial power capacity, the company is well-positioned to attract new tenants and contracts by the end of the year.